Given the pivotal roles that CD4 + T cell imbalance plays in human immune disorders, much interest centres on better understanding influences that regulate human helper T-cell subset dominance in vivo. Here, using primary CD4 + T cells and short-term T helper type 1 (Th1) and
Introduction
Imbalanced helper T cell subset function is a major contributor to many chronic immune diseases. Beyond their protective roles, excessive or misdirected T helper type 1 (Th1) cell activity is functionally important in various autoimmune diseases, whereas Th2-like cells play pivotal roles in allergies, asthma and many cancers.
1,2 Although many CD4 + T cell subtypes have been described in recent years, and there is now an appreciation of their plasticity, 1, [3] [4] [5] [6] [7] the broad model used of Th1-and Th2-like functional phenotypes provides a ready shorthand and useful paradigm to investigate contributions of CD4 + T cells to both protective and maladaptive immunity. The continuous rebalancing known to occur between different helper cell subtypes is controlled by many influences, including regulatory T cell activity, cytokine cross-regulation and production of anti-inflammatory cytokines by various 
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tissues. 8, 9 One other mechanism that plays an important role in such homeostasis is activation-induced cell death. The microenvironment for Th2-type diseases can actively promote activation-induced cell death of mostly Th1 but not Th2 cells, 10, 11 whereas the reverse can be seen in some diseases associated with overly exuberant Th1-type dominance. Hence, in any given disease condition, a varying proportion of cell death within distinct T-cell subsets can make an important contribution to immune polarization [12] [13] [14] and altered immune regulation. The mechanisms that contribute to such skewing are a focus of active research.
N-Methyl-D-aspartate receptors (NMDA-R) play fundamental roles in memory and learning. [15] [16] [17] Our understanding of their expression and function in immunology remains limited. Excitotoxicity is a Ca 2+ -dependent cell death pathway occurring in neurons that is triggered by excessive stimulation of NMDA-R by neurotransmitters such as glutamate. 18, 19 This type of cell death is clearly associated with Alzheimer's disease, Parkinson's disease, HIV-associated neurocognitive disorders, and several other neurodegenerative conditions. [20] [21] [22] Although cell biology and clinical studies to date have focused heavily on neuronal cells, interestingly, excitotoxicity can also be induced in extra-neuronal cells. 23, 24 Indoleamine 2,3-dioxygenase (IDO) contributes to Tcell imbalance; [25] [26] [27] IDO is the first and rate-limiting enzyme in tryptophan catabolism via the kynurenine pathway (Fig. 1a) that ultimately generates various breakdown products, collectively termed kynurenines. [28] [29] [30] Acting via NMDA-R, kynurenines exhibit diverse neurological activities. Quinolinic acid (QA) acts as an agonist, whereas kynurenic acid acts as an antagonist. 31, 32 In addition to our previous study, 26 data from murine models indicate that tryptophan breakdown products are crucial in Th2 cell function and survival, 33 tolerance in allergic airways 34 and airway smooth muscle function. 35, 36 Here, we sought to determine what role, if any, NMDA-R play in regulation of human CD4 + T-cell function. Specifically, we hypothesized that peripheral CD4 + T cells express functional NMDA-R in vivo and that they are up-regulated upon T cell receptor (TCR) ligation. We speculated that activation via this receptor acts on multiple key aspects of helper T cell function including proliferation, cytokine production and cell survival, and further, that NMDA-R agonists exhibit differential effects on T cell subsets that can lead to Th1 cell depletion and thereby indirectly enhance Th2-like dominance.
Materials and methods

Healthy volunteers and isolation of CD4
+ T cells Helper T-cell activation and assessment of NMDA-R agonist function
All cultures were carried out with glutamate-deficient medium. After 24 hr activation with anti-CD3/CD28 antibodies, primary peripheral blood mononuclear cells (PBMC) (2Á5 9 10 6 /ml), enriched primary CD4 + T cells (500 000/ml) or Th1-and Th2-driven cells (1Á0 9 10 6 cells/ml) were treated with NMDA-R agonists (100 lM NMDA or 40 lM QA (Sigma-Aldrich, Oakville, ON), alone or in the presence of NMDA-R-specific inhibitor MK-801 (10 lM, Sigma-Aldrich). In selected experiments, a-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA), an AMPA receptor agonist, or 1-amino-1,3-dicarboxycyclopentane (ACPD), a group I/II metabotropic glutamate receptor agonist, neither of which bind NMDA-R, were used at 100 lM (R&D Systems). Cells and supernatants were harvested at the times indicated. , 0Á5% weight/volume bovine serum albumin, 4 mM probenecid), distributed into flow cytometry tubes (2 9 10 6 cells/ml) and placed in a water bath at 37°until activation and immediate acquisition on the BD Canto II flow cytometer. Background intracellular Ca 2+ events were monitored by acquiring cells for 204 seconds without agonist stimulation then for the initial 50 seconds following agonist stimulation and further acquired up to 204 seconds. Positive controls consisted of cells activated with Ca 2+ ionophore A23187, also used to evaluate dye partitioning to optimize the concentration of Ca 2+ -sensitive dyes. Changes in intracellular Ca 2+ were measured using the kinetics function in FLOWJO software (Tree Star Inc., Ashland, OR).
NMDA-R1 expression on CD4 + T cells was detected by flow cytometry. Cells were treated with FcR Blocking Reagent then stained with rat monoclonal anti-NMDA-R1 (clone 5-1-G10) (Sigma-Aldrich) or isotype control, followed by Alexa Fluor 488 goat anti-rabbit antibody (Invitrogen, Carlsbad, CA), and anti-CD3/CD4 monoclonal antibodies (BD Biosciences, Mississauga, ON). Samples were analysed on a BD FACS Canto II flow ª 2017 John Wiley & Sons Ltd, Immunology, 153, 368-379 cytometer using DIVA software (BD Biosciences). Data were analysed using FLOWJO software, double gating on CD3 + and CD4 + cell populations.
Confocal laser scanning immunofluorescence
After 24 hr activation, cytospin samples of enriched CD4 + T cells were prepared on glass slides using 20% fetal bovine serum in PBS, dried and frozen. Cells were then fixed/permeabilized in 3% paraformaldehyde-0Á5% Triton X-100, blocked (0Á5% gelatine in PBS) and stained with polyclonal rabbit anti-NMDA-R1 (clone D65B7, Cell Signaling Technology, Danvers, MA) followed by Alexa Fluor 488 goat anti-rabbit immunoglobulin. Slides were analysed using an FV500 confocal microscope and FLU-OVIEW 1Á3 software (Olympus, Richmond Hill, ON).
Cell viability
The MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) assay was used to quantify cell viability (mitochondrial oxidation). Briefly, cells were activated with anti-CD3/28 for the period indicated, then treated with NMDA at the indicated concentrations. A 5 mg/ml MTT (yellow tetrazolium salt; Sigma-Aldrich) solution in PBS was added to cells at a ratio of 1 : 10 for the final 5 hr at 37°. Plates were centrifuged at 3009g, DMSO was added to solubilize the formazan crystals and optical density was read at 560 nm, with 670 nm background subtracted. The per cent of viable cells was calculated by setting the mean optical density of control groups as 100%.
Cell proliferation
Vybrant CFSE Cell Tracer Kit (Invitrogen) was used to label 1 9 10 6 cells/ml CD4 + T cells as well as Th1 and Th2 cells. Cells were then washed and resuspended in growth medium and cultured in the presence of various concentrations of NMDA or QA, followed by activation with anti-CD3/CD28 antibodies. Control samples consisted of mitomycin-C-treated T cells and parallel experiments of similarly treated unlabelled cells were performed. Cells were harvested after 5 days in culture, washed and examined using flow cytometry. Using the proliferation platform on the FLOWJO, a statistical model was used to track proliferation and determine the Proliferation Index for each treatment group.
Apoptosis
Apoptosis assays were performed after 2, 4 and 24 hr in culture by detecting Alexa Fluor 488 Annexin V and membrane permeability levels using the Vybrant Apoptosis Assay Kit along with Mitotracker Red CMXRos (Invitrogen) or TO-PRO-3 iodide (Invitrogen) and acquired on flow cytometry. Table S1 ) and Thunderbird SYBR qPCR Mix (Toyobo, Japan) in a CFX96 real-time PCR Detection System (Bio-Rad). For improved precision in quantifying changes in mRNA levels, standards were made for each primer set using Human Universal Reference Total RNA (Clontech, Mountain View, CA). Data are expressed as copy number/ng cDNA rather than fold induction. All data were normalized using 18s rRNA as housekeeping gene. Replicate assays of the same sample on independent days typically resulted in 5-10% CV in copy number values obtained.
Determination of cytokine protein levels
Cytokine levels in cryopreserved supernatants were determined using MesoScale Discovery (MSD, Gaithersburg, MD) electrochemiluminescence assays to quantify binding events on patterned arrays. To provide uniformity in comparing data between different plate lots, constant internal laboratory standards (Peprotech, Rocky Hill, NJ and R&D Systems, Minneapolis, MN) were used throughout the study. Samples and standards were incubated for 3 hr (instead of 2 hr) and plates were incubated with detection antibody for 3 hr (instead of 2 hr) before washing, with all other steps as per the manufacturers' recommendations. Analysis was on a SECTOR TM 2400 instrument (MSD). The operator was blind to the nature of all samples during processing, with subsequent statistical analysis also performed independently. Interassay variation was generally 5-10%.
Statistical analysis
Analyses were carried out with PRISM 5 software (GraphPad, San Diego, CA). Results were analysed for statistical significance using Wilcoxon or Mann-Whitney tests when nonparametric distributions occurred, and paired t-tests when parametric distributions were present. Friedman's test, a non-parametric test similar to the parametric repeated measures analysis of variance, was used to assess differences across multiple treatment concentrations. Two-tailed P-values were reported with differences considered significant if P < 0Á05. Throughout the study, each n value represents the number of independent donors examined.
Results
CD4
+ T cell activation induces strong NMDA-R1 upregulation Although NMDA-R expression by resting lymphocytes is well established, the impact of TCR-mediated activation on receptor expression is poorly understood. We initially focused on NMDA-R1, an essential subunit for functional NMDA-R expression 39 in primary CD4 + T cells obtained from peripheral blood following acute TCR-mediated activation with anti-CD3/CD28 antibodies. Figure 1(b) demonstrates that NMDA-R1 expression was present at low levels in resting cells in vivo. Upon activation, it was rapidly enhanced with median 600-fold increases by 4 hr, peak expression at 24 hr (median 1500-fold enhanced) and was sustained for at least a week. Subsequent experiments with 18 additional individuals demonstrated that in total 23 of the 27 healthy adults examined up-regulated NMDA-R1 at the 24 hr time-point following TCR stimulation. NMDA-R1 protein expression was subsequently confirmed by flow cytometry of TCR-activated CD4 + T cells (Fig. 1c ) and confocal laser scanning microscopy (Fig. 1d) .
Functional activity of activated primary CD4 + T cells is altered upon NMDA-R stimulation
To determine if NMDA-R1 expression was functional, intracellular Ca 2+ flux was assessed. NMDA is a synthesized ligand that does not typically occur in nature. It is used here to complement glutamate or QA (two natural NMDA-R ligands) and because of its specificity for NMDA-R, whereas glutamate can bind to receptors other than the NMDA-R. TCR-activated primary human CD4 + T cells were cultured with NMDA or glutamate. Dosedependent increases in intracellular Ca 2+ (Fig. 2) were evident, with specific, non-competitive, NMDA-R inhibitor MK-801 largely abolishing such responses. NMDA-R specificity was also confirmed using independent glutamate receptor subtype-specific agonists; AMPA (an AMPA receptor agonist) (Fig. 2c) and ACPD (a group I/ II metabotropic glutamate receptor agonist) (Fig. 2d) . Neither of these stimulated Ca 2+ flux.
NMDA-R stimulation has a differential impact on Type 1 versus Type 2 cytokine responses
To determine if there was an impact of NMDA-R agonist exposure on cytokine production by fresh human T cells directly ex vivo, we stimulated PBMC from 12 asymptomatic donors with anti-CD3/CD28 alone and in the presence of NMDA or QA. QA, a physiological tryptophan breakdown product that acts as an NMDA-R agonist in the nervous system, 31,32 is also found in blood and local tissues. Type 1 cytokine production was substantially decreased in the presence of either NMDA-R ligand [ Fig. 3a, i.e. median decreases 65% (P < 0Á005) and 75% (P = 0Á002) for IFN-c; 40% (P = 0Á015) and 50% (P = 0Á002) for tumour necrosis factor-a (TNF-a)]. Conversely, type 2 cytokine production stimulated by anti-CD3/CD28 monoclonal antibodies (Fig. 3b left columns) was not hindered. Recognizing that anti-CD3/CD28 is a strong type 1 stimulus but relatively weak stimulus of type 2 cytokine production 40 and that the positive controls in these experiments exhibited low levels of cytokine production, phytohaemagglutinin (PHA) was used as a recognized stimulus of type 2 recall responses. PHA elicited 10-fold to 100-fold increased type 2 responses compared with those elicited with anti-CD3/CD28 (Fig. 3b, right  columns) . None of these robust type 2 responses were inhibited in the presence of QA or NMDA.
To determine if the selective effect of NMDA or QA on type 1 responses was linked to increased IL-10 production, the impact of NMDA-R activation was assessed in responses elicited by either anti-CD3/CD28 or PHA activation. Interleukin-10 production was not affected in either case.
Collectively these data demonstrate that NMDA-R agonists are capable of eliciting Ca 2+ flux in primary human CD4 + T cells and of selectively inhibiting type 1 cytokine production, while sparing type 2 cytokine responses.
Impact of NMDA-R triggering on cell survival
To examine the effect of NMDA-R ligation on survival of primary CD4 + T cells, fresh CD4 + T cell-enriched populations were stimulated with anti-CD3/CD28 monoclonal antibodies in the presence of increasing concentrations of NMDA. NMDA-R stimulation was found to dose-dependently decrease cellular viability (Fig. 3c) .
Differential sensitivity of Th1 versus Th2 polarized cells to NMDA-R regulation
To assess how NMDA-R stimulation might differentially affect more fully committed human Th1 versus Th2 cells, we induced short-term Th1 and Th2 cell lines in vitro using CD4 + T cells from five different individuals. Realtime PCR, ELISA and intracellular staining for IFN-c and IL-4 followed by flow cytometric analysis were used to confirm typical Th1 and Th2 cell phenotypes in the 10 lines derived. Transient Ca 2+ flux was evident in both Th1-and Th2-driven cell lines (Fig. 4a) . In the nine experiments conducted with Th1 cells, each demonstrated robust Ca 2+ flux. Considerably more variability was evident with Th2 lines, with 8 of 11 experiments exhibiting weak or undetectable Ca 2+ flux. Hence, although both cell types are capable of exhibiting NMDA-R-dependent activation, it was most intensely and consistently evident in Th1-driven cells. Use of QA to elicit activation revealed similar strong responses by Th1 clones whereas Th2 clones were usually weakly responsive or unresponsive to this physiological NMDA-R ligand (Fig. 4b) . As seen above for fresh (largely uncommitted) primary T cell populations directly ex vivo, IFN-c and TNF-a production driven by TCR engagement was reduced in the presence of NMDA or its physiological counterpart, QA. Cytokine production by Th2 cells was again, unaffected (Fig. 5 ).
We therefore directly tested the hypothesis that exposure to NMDA-R agonists differentially affects proliferation and/or survival of committed Th1 versus Th2 cells. CFSE-loaded Th1 and Th2 cultures were activated with anti-CD3/CD28 mAbs for 24 hr then cultured in the presence of different concentrations of NMDA. Figure 6(a,b) demonstrates that NMDA had no impact on the proliferation of TCR-induced Th2-driven proliferation over 11 independent experiments, even at concentrations up to 1600 lM. Conversely, Th1-driven cell proliferation was markedly inhibited by NMDA, even at 100 lM (P < 0Á001). Figure 6 (b) provides sample CFSE data. Similarly, NMDA resulted in sharp decreases in Th1 cell numbers whereas Th2 cultures exposed to 200 lM NMDA were unchanged (Fig. 6c,d ). Collectively these data indicate that differential cytokine production and proliferative capacity of Th1 versus Th2 cell lines were attributable to an increased frequency of physiological cell death among fully committed Th1 versus Th2 cells upon NMDA-Rdependent triggering.
TCR-stimulated Th1 and Th2 lines cultured with NMDA (200 lM) were stained with TO-PRO-3 and Annexin V then analysed by flow cytometry (Fig. 7) . Th1 cells exhibited strong sensitivity to NMDA (mean 33% death at 24 hr), whereas only a small proportion of Th2 cells died. These effects of NMDA were largely blocked in the presence of MK-801 (10 lM). This pattern of differential Th1 versus Th2 cell sensitivity with respect to cell death following NMDA-R ligation was also evident in independent experiments using physiological ligand QA (40 lM) (Fig. 7c) .
Discussion
There is increasing recognition of the importance of neurotransmitter signalling within the human immune system. 41, 42 In this study, we found that anti-CD3/CD28 activation induces mature human CD4 + T cells to markedly up-regulate functional NMDA-R on their surface.
Specific stimulation with NMDA, or with the physiological tryptophan metabolite QA, resulted in reduced expression of Th1-like cytokine production concomitant with unaltered Th2-like or IL-10 responses. Th1, but not Th2, cells exhibited reduced proliferation upon TCR-dependent activation. The mechanism underlying these differential effects on Th1-versus Th2-like function was linked to a pronounced susceptibility of Th1 cells, and relative resistance of Th2 cells, to NMDA-R-dependent physiological cell death. This differential sensitivity to cell death in Th1 versus Th2-like cells is the first report of which we are aware that demonstrates differential responses of CD4 + T cell subsets to NMDA-R stimulation. The data suggest that NMDA-R-mediated cytotoxicity of Th1 cells could contribute to the CD4 + T cell imbalance that is characteristic of a range of human chronic immune disorders, including allergies and asthma.
This observation, that NMDA-R stimulation selectively modulates TCR-dependent Th1 versus Th2 function and survival has analogies to NMDA-R-driven effects on neurons, where both neuroprotective and neurotoxic outcomes are observed. In the nervous system, NMDA-R stimulation can lead cells to death when they are excited beyond homeostatic levels. 43 An overabundance of cytosolic Ca 2+ results in over-activation of Ca 2+ -dependent degradative enzymes leading to cell death. 44 Microglia can release glutamate, promoting neurotoxicity in neurons expressing NMDA-R. 45 In the immune system, glutamate from antigen-presenting cells contributes to regulate glutamate levels in the microenvironment of lymph nodes that may modulate T cell cytokine secretion. 46 Similarly, Banday et al. recently published findings from the NOD model of type 2 diabetes that glutamic acid is a potent inducer of apoptosis among healthy murine b cells. 47 Physical interaction of glutamate and T cells has been demonstrated using radio-labelled glutamate. 48 In addition to elevated glutamate levels in white brain matter of patients with multiple sclerosis, 49 glutamate levels were found to be elevated in plasma of patients with several immune diseases, including HIV infection, 50 ,51 cancer, 52, 53 and rheumatoid arthritis. 54, 55 Here, glutamate, NMDA and QA were all used to examine NMDA-R function in peripheral human CD4 + T cells. Importantly, although glutamate is an agonist for NMDA-R, it can bind to several different subtypes of receptors. 56 Using the synthetic but highly specific NMDA-R ligand NMDA allowed for highly targeted stimulation. In contrast, QA, a tryptophan metabolite, exists in vivo and has a higher excitatory activity than other kynurenines. 57 QA promotes apoptosis in oligodendrocytes, 58 neurons 59, 60 and astrocytes, 61 as well as thymocytes 62 at pathophysiological concentrations. In the immune system, dendritic cells 63 as well as eosinophils 26 are known to express IDO, which catalyses kynurenine synthesis. Hence, in addition to glutamate, QA via IDO activity can be an efficient source of NMDA-R stimulation in vivo. Hence, as found here, NMDA-R ligands are implicated as important modulators of immune capacity. In contrast, unlike the mature peripheral T cells or Th1/Th2-driven lines described above, thymocytes in isolation were found to exhibit neither NMDA-R nor NMDA-R-dependent functional activity (i.e. Ca 2+ flux). In 2011, Affaticati et al. 64 proposed, based on experiments examining murine thymocyte development, that in T cell-dendritic cell co-cultures an un-identified dendritic cell-derived glutamate agonist induces Ca 2+ flux and caspase-3 activation in immature T cells. Hence, as found here, NMDA-R ligands were implicated as important modulators of immune capacity. In 2014, Beurel et al. 65 reported that during culture of murine thymocytes with astrocytes, glutamate was an effective promoter of naive CD4 + T cell commitment to Th1 differentiation. In a collagen-induced arthritis model, in vivo use of an NMDA-R antagonist enhanced the expression of Foxp3 in splenic T cells, resulted in increased CD4 + CD25 + regulatory T cells and attenuated the development of arthritis. 66 If reproduced in humans, these data suggest that, as for many other biological response modifiers, the same molecule (or its metabolites) may exert distinct effects on the physiology of naive versus fully committed cells. Notwithstanding the fact that different experimental designs and species were used, these data reinforce the concept of a multifaceted role for NMDA-R in both generation and function of mature immune systems. 67 This study has several limitations. Unbalanced Th1-like and Th2-like activities play key roles in the pathogenesis and maintenance of many human immune disorders. We recognize that multiple other helper T cell subset phenotypes and regulatory T cell phenotypes have been described over the last decade. The roles that NMDA-R expression may play in the initial induction, or in the protracted maintenance of other subsets remains to be examined. Second, although the data demonstrate differential sensitivity of a broad array of Th1 versus Th2 function among fresh CD4 + T cells ex vivo and their in vitro derived T cell line counterparts, we did not explicitly quantify NMDA-R subunit density on Th1 and Th2 lines. In addition, the experiments on helper T cell physiology in this report were performed with PBMC, enriched
CD4
+ T cells, and Th1-or Th2-driven cell lines of healthy adults. Future studies will need to examine CD4 + T cell function, as well as putatively differential in vivo expression of physiological NMDA-R ligands, in volunteers with well-established type 1-or type 2-biased chronic inflammatory diseases.
In summary, this study demonstrates that upon TCRmediated activation, human CD4 + T cells up-regulate functional NMDA-R and that the triggering of such receptors by biologically relevant ligands causes a differential impact on cytokine production, proliferation and cell viability, both ex vivo in fresh helper T cells, and in Th1-versus Th2-driven cell lines. The selective and pronounced cytotoxicity displayed by Th1 cells provides insight into a mechanism underlying T cell imbalancemediated disorders that share aspects analogous to excitotoxicity in the nervous system. Taken with recent advances in neurology, the findings suggest opportunities 19 for better understanding of, and perhaps intervention into, immune processes that underlie the persistence of well-established human maladaptive immune responses and clinical disease. Canada Research Chairs funding for KTH, the Alberta 
